EASIX for Prediction of Outcome in Hospitalized SARS-CoV-2 Infected Patients

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in immunology Ročník 12; s. 634416
Hlavní autoři: Luft, Thomas, Wendtner, Clemens-Martin, Kosely, Florentina, Radujkovic, Aleksandar, Benner, Axel, Korell, Felix, Kihm, Lars, Bauer, Matthias F., Dreger, Peter, Merle, Uta
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 23.06.2021
Témata:
Adolescent
Adult
Aged
Aged, 80 and over
angiopoietin-2 (Ang-2)
Biomarkers - metabolism
COVID-19 - diagnosis
COVID-19 - mortality
EASIX
endothelial activation and stress index
Endothelial Cells - physiology
Female
Hematopoietic Stem Cell Transplantation
Hospitalization
Humans
Immunology
Male
Middle Aged
Prognosis
Prospective Studies
Respiration, Artificial
SARS-CoV-2 - physiology
SARS-CoV2 (COVID- 19)
Severity of Illness Index
soluble thrombomodulin
suppressor of tumorigenicity 2 (ST2)
Survival Analysis
Transplantation, Homologous
Treatment Outcome
Young Adult
angiopoietin-2 (Ang-2)
soluble thrombomodulin
prediction of outcome
endothelial activation and stress index
suppressor of tumorigenicity 2 (ST2)
EASIX
SARS-CoV2 (COVID- 19)
ISSN:1664-3224, 1664-3224
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has evoked a pandemic that challenges public health-care systems worldwide. Endothelial cell dysfunction plays a key role in pathophysiology, and simple prognosticators may help to optimize allocation of limited resources. Endothelial activation and stress index (EASIX) is a validated predictor of endothelial complications and outcome after allogeneic stem cell transplantation. Aim of this study was to test if EASIX could predict life-threatening complications in patients with COVID-19. SARS-CoV-2-positive, hospitalized patients were enrolled onto a prospective non-interventional register study (n=100). Biomarkers were assessed at hospital admission. Primary endpoint was severe course of disease (mechanical ventilation and/or death, V/D). Results were validated in 126 patients treated in two independent institutions. EASIX at admission was a strong predictor of severe course of the disease (odds ratio for a two-fold change 3.4, 95%CI 1.8-6.3, p<0.001), time to V/D (hazard ratio (HR) for a two-fold change 2.0, 95%CI 1.5-2.6, p<0.001) as well as survival (HR for a two-fold change 1.7, 95%CI 1.2-2.5, p=0.006). The effect was retained in multivariable analysis adjusting for age, gender, and comorbidities and could be validated in the independent cohort. At hospital admission EASIX correlated with increased suppressor of tumorigenicity-2, soluble thrombomodulin, angiopoietin-2, CXCL8, CXCL9 and interleukin-18, but not interferon-alpha. EASIX is a validated predictor of COVID19 outcome and an easy-to-access tool to segregate patients in need for intensive surveillance.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Helena Stabile, Sapienza University of Rome, Italy
This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
Reviewed by: Saikat Majumder, University of Pittsburgh, United States; Tatiani Uceli Maioli, Federal University of Minas Gerais, Brazil
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.634416